Greten, Tim F https://orcid.org/0000-0002-0806-2535
Abou-Alfa, Ghassan K
Cheng, Ann-Lii
Duffy, Austin G
El-Khoueiry, Anthony B.
Finn, Richard S
Galle, Peter R
Goyal, Lipika
He, Aiwu Ruth
Kaseb, Ahmed O
Kelley, Robin Kate
Lencioni, Riccardo
Lujambio, Amaia
Mabry Hrones, Donna
Pinato, David J https://orcid.org/0000-0002-3529-0103
Sangro, Bruno
Troisi, Roberto I
Wilson Woods, Andrea
Yau, Thomas
Zhu, Andrew X
Melero, Ignacio https://orcid.org/0000-0002-1360-348X
Clinical trials referenced in this document:
Documents that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
https://doi.org/10.1136/jitc-2022-005414
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/jitc-2021-002794
574 Blood-based extracellular matrix biomarkers are correlated with prognostic and fibrotic-related clinical characteristics and liver function markers in patients with advanced hepatocellular carcinoma
https://doi.org/10.1136/jitc-2022-sitc2022.0574
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
https://doi.org/10.1200/jco.22.00972
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
https://doi.org/10.1136/gutjnl-2014-307990
Dynamic human immune and tumour cells cross-talk in PDX-humanised mice warrants checkpoint inhibitor cancer immunotherapies assessment
https://doi.org/10.1136/gutjnl-2018-316467
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/jitc-2021-002794
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.4100
Documents that mention this clinical trial
1282 Concordance analysis of AI-powered CD8 quantification and automated CD8 topology with manual histopathological assessment across seven solid tumor types
https://doi.org/10.1136/jitc-2022-sitc2022.1282
Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model
https://doi.org/10.1136/jitc-2022-005414
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/jitc-2021-002794
574 Blood-based extracellular matrix biomarkers are correlated with prognostic and fibrotic-related clinical characteristics and liver function markers in patients with advanced hepatocellular carcinoma
https://doi.org/10.1136/jitc-2022-sitc2022.0574
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
https://doi.org/10.1200/jco.22.00972
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches
https://doi.org/10.1136/gutjnl-2014-307990
Dynamic human immune and tumour cells cross-talk in PDX-humanised mice warrants checkpoint inhibitor cancer immunotherapies assessment
https://doi.org/10.1136/gutjnl-2018-316467
Documents that mention this clinical trial
Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
https://doi.org/10.1200/jco.2023.41.16_suppl.4004
Addendum 1: <i>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma</i>
https://doi.org/10.1136/jitc-2021-002794add1
Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC).
https://doi.org/10.1200/jco.2023.41.4_suppl.551
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
https://doi.org/10.1136/jitc-2021-002794
Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
https://doi.org/10.1200/jco.23.01462
Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC).
https://doi.org/10.1200/jco.2023.41.16_suppl.4073
591 Immunogenicity of durvalumab: analysis of pooled pan-tumor data
https://doi.org/10.1136/jitc-2022-sitc2022.0591
146 CD68 expression in tumor cells is associated with poor clinical outcomes following immunotherapy and immunotherapy plus chemotherapy combination therapies
https://doi.org/10.1136/jitc-2024-sitc2024.0146
Immunotherapy for hepatocellular carcinoma: current status and future perspectives
https://doi.org/10.1136/esmoopen-2018-000455
Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective (Results)
https://doi.org/10.1136/bmjopen-2024-090992